Controls severe nausea and vomiting. ANDA 216202, held by Novitium Pharma. Prochlorperazine Maleate.
As of Nov 16, 2026, ANDA 216202 (Prochlorperazine Maleate), held by Novitium Pharma, was first approved by FDA on Jun 13, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS & USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2022 | Original application | Approved | None posted |
| Prochlorperazine MaleateEQ 5MG BASE · tablet;oral | Prochlorperazine Maleate | Rx |
| Prochlorperazine MaleateEQ 10MG BASE · tablet;oral | Prochlorperazine Maleate | Rx |
| Jan 22, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 13, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters